[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"syringomyelia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:syringomyelia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,63,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100544966","subarachnoid-subarachnoid-s-s-bypass-versus-adhesion-lysis-in-spinal-arachnoiditis-and-syringomyelia-100544966",false,"NCT06375759","Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and Syringomyelia","Inclusion Criteria:\n\n* 1\\) history of traumatic spinal cord injury or other infection; 2) evidence of progressive neurological deficit, and\u002For pain syndrome; 3) MRI showing a syringomyelia due to spinal trauma or other infection; and 4) minimum follow-up period of more than 1 year.\n\nExclusion Criteria:\n\n* Chiari-malformation, myelomalacia, subarachnoid cyst, syringomyelia due to other spinal diseases (such as degenerative spinal disease)","ALL","18 Years","80 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","To determine whether Subarachnoid-Subarachnoid (S-S) Bypass results in better patient outcomes with fewer complications and improved quality of life compared to intradural adhesion lysis in individuals with Spinal Arachnoiditis and Syringomyelia.",[26],"Syringomyelia",[28],"syringomyelia","RECRUITING","2024-04-16",{"date":32,"type":33},"2024-04-19","ACTUAL",{"date":35,"type":20},"2024-04",{"date":37,"type":20},"2027-04",{"name":39,"class":40},"Xuanwu Hospital, Beijing","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100539786","phase-2-the-therapeutic-effect-of-betaine-in-syringomyelia-100539786","NCT06308367","The Therapeutic Effect of Betaine in Syringomyelia","The Effect of Betaine in Refractory Syringomyelia（RS）","Inclusion Criteria:\n\n* Contraindication to duraplasty and shunting treatment due to history or high risk of severe adverse effects,\n* non-effective response to duraplasty and shunting treatment in 12 months prior to study entry.\n* Estimated life expectancy must be greater than 12 months.\n* Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document.\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Participants have a cardiometabolic disease for which they take prescribed medications\n* Evidence of tumor metastasis, recurrence, or invasion;\n* History of psychiatric diseases ;\n* History of seizures;\n* History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months;\n* New York Heart Association Grade II or greater congestive heart failure;\n* Serious and inadequately controlled cardiac arrhythmia;\n* Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, -history of aortic dissection;\n* Severe infection;\n* History of allergy to relevant drugs;\n* Pregnancy, lactation, or fertility program in the following 12 months;\n* History or current diagnosis of peripheral nerve disease;\n* Abnormal in liver and renal function;\n* Active tuberculosis;\n* Transplanted organs;\n* Human immunodeficiency virus;\n* Participation in other experimental studies.",{"count":50,"type":20},30,[52],"PHASE2","Purpose: This clinical trial aims to evaluate the indications, therapeutic effects and side effects of betaine in refractory syringomyelia.\n\nPrimary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before betaine usage.",[26],"2024-03-11",{"date":57,"type":33},"2024-03-13",{"date":59,"type":20},"2024-03",{"date":61,"type":20},"2028-03",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},"100536689","phase-2-the-therapeutic-effect-of-thalidomide-in-syringomyelia-100536689","NCT06268093","The Therapeutic Effect of Thalidomide in Syringomyelia","The Effect of Thalidomide in Refractory Syringomyelia（RS）: a Phase II Clinical Trial","Inclusion Criteria:\n\n* Contraindication to duraplasty and shunting treatment due to history or high risk of severe adverse effects,\n* or non-effective response to duraplasty and shunting treatment in 12 months prior to study entry.\n* Estimated life expectancy must be greater than 12 months.\n* Routine laboratory studies: bilirubin \\\u003C\u002F=1.0 \\* upper limits of normal (ULN); aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)\\\u003C 1.0 \\* ULN; creatinine \\\u003C1.0 \\* ULN; white-cell count \\>\u002F= 4,000 per cubic millimeter; neutrophils count \\>\u002F=1500 per cubic millimeter platelets \\>\u002F= 100,000 per cubic millimeter; Hb \\>\u002F=110 gram per millilitres; PT, APTT, INR in a normal range.\n* Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document.\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Evidence of tumor metastasis, recurrence, or invasion;\n* History of psychiatric diseases ;\n* History of seizures;\n* History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months;\n* New York Heart Association Grade II or greater congestive heart failure;\n* Serious and inadequately controlled cardiac arrhythmia;\n* Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, history of aortic dissection;\n* Severe infection;\n* History of allergy to relevant drugs;\n* Pregnancy, lactation, or fertility program in the following 12 months;\n* History or current diagnosis of peripheral nerve disease;\n* Abnormal in liver and renal function;\n* Active tuberculosis;\n* Transplanted organs;\n* Human immunodeficiency virus;\n* Participation in other experimental studies.",{"count":50,"type":20},[52],"Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia.\n\nPrimary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.",[26,74],"Thalidomide","2024-02-19",{"date":77,"type":33},"2024-02-20",{"date":79,"type":20},"2024-02",{"date":81,"type":20},"2028-02",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100516952","development-of-a-patient-reported-outcome-measure-for-chiari-malformation-and-syringomyelia-100516952","NCT06011226","Development of a Patient-reported Outcome Measure for Chiari Malformation and Syringomyelia","BCS-score","Inclusion Criteria:\n\nCriteria common to all subjects included in the study\n\n* Age \\> 18 years\n* Subject understanding French Patients included in Phase I\n* Subject with signed informed consent Patients included in phase II\n* Patient not opposed to study participation\n\nPatients Chiari only group:\n\n* Isolated descent of cerebellar tonsils \\> 5 mm below McRae's line (no associated syringomyelia)\n\nPatients syringomyelia only group:\n\n* Presence of an intramedullary fluid cavity secondary to circulatory disturbance of cerebrospinal fluid of non foraminal origin (no Chiari)\n\nPatients Chiari with Syringomyelia group:\n\n* Presence of Chiari malformation (tonsils \\> 5 mm below McRae's line) AND foraminal syringomyelia.\n\nExclusion Criteria:\n\n* Insufficient command of French\n* Minor or protected adult (guardianship, curatorship, safeguard of justice)\n* Diagnosis of Chiari and\u002For syringomyelia not proven by an MRI scan\n* Pregnant or breast-feeding",{"count":91,"type":20},60,"OBSERVATIONAL","Chiari malformation corresponds to the herniation of cerebellar tonsils into the foramen magnum resulting in obstruction of cerebrospinal fluid circulation, which may eventually lead to the formation of an intramedullary cavity called syringomyelia.\n\nChiari and syringomyelia can be responsible of variable symptoms, based on which neurosurgeons might propose surgical treatment. Yet, there is no properly developped and validated patient reported outcome measure (PROM) to assess the clinical severity of Chiari malformation and\u002For syringomyelia. The lack of such evaluation tool is a major issue to determine the optimal therapeutic strategy and to achieve a standardized and reproducible follow-up.",[26,95],"Chiari Malformation",[26,95,97],"patient-reported outcome measure","NOT_YET_RECRUITING","2023-09-18",{"date":101,"type":33},"2023-09-21",{"date":103,"type":20},"2023-09",{"date":105,"type":20},"2026-12",{"name":107,"class":40},"Assistance Publique - Hôpitaux de Paris"]